AIM ImmunoTech Inc. (AIM)
AIM ImmunoTech Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Ocala, FL, US. The stock last traded at $0.19, down 6.49% on the session, giving a market capitalisation of $647,013. On trailing twelve-month figures it carries a trailing P/E of -0.05, a net margin of -15021.1%. Its beta of 1.19 implies it has historically moved more than the broad market.
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.
AIM ImmunoTech Inc. is most often compared with the following Healthcare names: